PROTAC Compounds Degrade RIP2 Kinase via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to inhibit RIP2 kinase activity are limited, particularly in effectively addressing auto-inflammatory diseases characterized by dysregulated RIP2-dependent signaling, and there is a need for selective downregulators or degraders that can reduce RIP2 expression to block pro-inflammatory signaling.
Innovation Solution
Development of PROTAC compounds that simultaneously bind to RIP2 kinase and an E3 ubiquitin ligase, such as von Hippel-Lindau tumor suppressor, to promote ubiquitination and degradation of RIP2 kinase, using specific substructures and linkers to enhance targeting and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to block RIP2 kinase activity, then pro-inflammatory signaling is inhibited, but the effectiveness is limited and RIP2 expression levels remain unchanged
Solution Approach 1:
Instead of inhibiting RIP2 kinase activity through small molecule inhibitors, the invention inverts the approach by promoting RIP2 degradation through PROTAC-mediated ubiquitination. This fundamental reversal from activity inhibition to protein degradation provides more effective and versatile control over RIP2-dependent signaling pathways.
Solution Approach 2:
The invention introduces E3 ubiquitin ligases (such as VHL, IAPs, and CRL4) as intermediary proteins that mediate the degradation of RIP2 kinase. These ligases act as bridges between the PROTAC compounds and the proteasome system, enabling targeted degradation of RIP2 while avoiding the limitations of direct kinase inhibition.
2Reliability
If PROTAC compounds are designed to simultaneously bind RIP2 kinase and E3 ubiquitin ligase, then RIP2 degradation is achieved, but molecular complexity increases
Solution Approach 1:
The PROTAC compounds are segmented into distinct functional modules: a RIP2-binding moiety (such as quinoline or pyrimidine derivatives), a linker region, and an E3 ligase-binding moiety (such as VHL, IAP, or CRL4 binders). This segmentation allows each module to perform its specific function while maintaining overall molecular organization and facilitating rational drug design.
Solution Approach 2:
The PROTAC compounds represent composite molecular structures that integrate multiple pharmacophores with different functions into a single hybrid molecule. This composite approach combines the RIP2-inhibiting properties of small molecules with the protein-degradation capabilities of PROTAC technology, creating molecules with enhanced therapeutic potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively degrade RIP2 kinase, providing a therapeutic benefit by reducing RIP2-dependent pro-inflammatory signaling, thereby treating auto-inflammatory diseases mediated by RIP2 kinase activity.
Implementation Method 1
promote ubiquitination and degradation of RIP2 kinase
Data Source
AI summary
The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.